Litigation Details for Bayer Pharma AG v. Watson Laboratories Inc (D. Del. 2014)

Bayer Pharma AG v. Watson Laboratories Inc (D. Del. 2014)

Docket		Date Filed	2014-06-17
Court	District Court, D. Delaware	Date Terminated	2016-05-02
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	8,613,950
Link to Docket	External link to docket

Details for Bayer Pharma AG v. Watson Laboratories Inc (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-17				External link to document

Bayer Pharma AG v. Watson Laboratories, Inc. 1:14-cv-00760 Patent Litigation Summary

Last updated: August 2, 2026

Bayer Pharma AG v. Watson Laboratories, Inc., No. 1:14-cv-00760, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Watson's abbreviated new drug application for a generic version of Bayer's Yaz oral contraceptive. Bayer asserted U.S. Patent No. 8,673,921, which covered a contraceptive regimen using drospirenone and ethinyl estradiol. The district court held the asserted claims obvious, and the Federal Circuit affirmed in 2017. The decision eliminated the principal patent-based barrier to Watson's generic launch. [1]

What drug and patent were at issue in Bayer v. Watson?

The case concerned Yaz, a combined oral contraceptive containing:

Product	Active ingredients	Dosage form	Brand company
Yaz	Drospirenone 3 mg and ethinyl estradiol 0.02 mg	Oral tablet	Bayer

Bayer sued Watson after Watson filed an ANDA containing a Paragraph IV certification challenging the relevant patent. Bayer alleged that Watson's proposed generic product would infringe U.S. Patent No. 8,673,921.

The patent covered a contraceptive dosing regimen using drospirenone and ethinyl estradiol. The regimen used 24 active tablets followed by four hormone-free tablets, corresponding to the commercially important Yaz dosing schedule. [1]

What patent did Bayer assert?

Patent	Subject matter	Litigation outcome
U.S. Patent No. 8,673,921	Oral contraceptive regimen using drospirenone and ethinyl estradiol	Claims held obvious; Federal Circuit affirmed

The asserted patent was a method-of-use and regimen patent rather than a patent covering a new chemical entity. That distinction limited the scope of Bayer's exclusivity. The patent protected the claimed administration schedule and composition parameters, not every possible contraceptive use of drospirenone or ethinyl estradiol.

When was the Bayer v. Watson case filed?

Bayer filed the action in 2014 in the District of Delaware under case number 1:14-cv-00760. The complaint followed Watson's Paragraph IV certification against the Yaz-related patent.

A Paragraph IV certification states that the challenged patent is invalid, unenforceable, or will not be infringed by the proposed ANDA product. Under the Hatch-Waxman Act, a Paragraph IV notice gives the patent holder 45 days to file suit. A timely suit generally triggers a statutory stay of FDA approval for up to 30 months, subject to earlier termination or court action. [2]

The filing therefore created a regulatory approval obstacle for Watson while the patent case proceeded.

What did the district court decide?

The district court ruled that the asserted claims of U.S. Patent No. 8,673,921 were obvious under Section 103 of the Patent Act.

The court's analysis focused on whether a person of ordinary skill in the art would have been motivated to use the claimed drospirenone and ethinyl estradiol regimen and whether the prior art created a reasonable expectation of success.

The district court determined that the claimed regimen represented an obvious modification of known oral contraceptive regimens. Bayer appealed to the U.S. Court of Appeals for the Federal Circuit.

Why did the Federal Circuit affirm the patent invalidity ruling?

The Federal Circuit affirmed the district court in Bayer Pharma AG v. Watson Laboratories, Inc., 874 F.3d 1316 (Fed. Cir. 2017). [1]

The appellate court accepted the district court's conclusion that the prior art supplied both:

1. A motivation to pursue the claimed contraceptive regimen; and
2. A reasonable expectation that the regimen would work for contraception.

The Federal Circuit rejected Bayer's argument that the prior art did not adequately support the claimed combination or dosing schedule. The court also declined to treat the claimed regimen's clinical and commercial advantages as sufficient to overcome the obviousness showing.

The ruling illustrates the risk associated with pharmaceutical regimen patents that combine known active ingredients and known dosing concepts. A patent may claim a commercially successful dosing schedule, but commercial success does not establish nonobviousness when the prior art provides a reason to adopt the regimen.

What was the final litigation outcome?

The final appellate outcome was adverse to Bayer:

Issue	Result
Infringement dispute	Resolved through invalidity ruling
Patent validity	Asserted claims held obvious
District court judgment	Affirmed
Federal Circuit appeal	Bayer lost
Injunction against Watson	No continuing patent basis after invalidity ruling
Settlement	No settlement outcome reported in the controlling Federal Circuit decision
Biosimilar issue	Not applicable

Because the asserted claims were held invalid, Bayer could not use the patent to block Watson's ANDA product. The decision removed the primary patent litigation barrier associated with the case.

How strong was Bayer's patent estate for Yaz?

The litigation indicates that Bayer's Yaz estate had material vulnerability in its secondary patent protection.

New chemical entity protection

The active ingredients in Yaz were known pharmaceutical compounds. Bayer therefore did not rely on a fresh composition-of-matter patent for the product at issue in this case.

Formulation protection

The asserted patent was tied to the product's formulation and dosing regimen, but the Federal Circuit treated the claimed combination as an obvious development from the prior art. The decision weakened the value of the regimen patent as a long-term barrier to generic competition.

Method-of-use protection

The patent's method and regimen claims were important because they sought to protect the specific contraceptive use and administration schedule. Those claims failed on obviousness grounds.

Manufacturing and process protection

The reported decision did not establish a surviving manufacturing-process barrier against Watson. The case therefore did not create a meaningful process-patent impediment to generic competition.

Overall, the estate was weaker than a portfolio centered on an unexpired composition-of-matter patent. Its principal vulnerability was reliance on a narrow regimen claim that the courts found predictable in view of the prior art.

What was the Orange Book status of the patent?

U.S. Patent No. 8,673,921 was an Orange Book-listed patent associated with Bayer's Yaz product at the time of the ANDA litigation. The Orange Book listing supported Bayer's Hatch-Waxman action after Watson's Paragraph IV certification. [3]

The listing did not guarantee enforcement success. Orange Book listing establishes the statutory framework for an ANDA patent challenge, but the patent remains subject to invalidity and noninfringement defenses.

After the Federal Circuit affirmed invalidity, the patent could no longer function as an enforceable patent barrier against Watson for the challenged product.

Did the case involve a Paragraph IV challenge?

Yes. Watson's ANDA included a Paragraph IV certification directed to Bayer's listed patent. Bayer responded with an infringement action, creating the standard Hatch-Waxman litigation sequence:

1. Watson submitted an ANDA for a generic Yaz product.
2. Watson notified Bayer of its Paragraph IV position.
3. Bayer filed suit within the statutory 45-day period.
4. The action triggered the Hatch-Waxman approval stay.
5. The district court held the asserted patent claims obvious.
6. The Federal Circuit affirmed.

The Paragraph IV process allowed Watson to challenge the patent before commercial launch rather than wait for a conventional infringement action after launch.

Were there settlement agreements or licensed generic terms?

The controlling appellate decision resolved the matter through a validity judgment rather than a reported settlement. No licensed-entry date, authorized-generic arrangement, or reverse-payment settlement is identified in the Federal Circuit opinion. [1]

That distinguishes this case from many pharmaceutical patent disputes in which the parties settle before trial and establish a confidential or negotiated generic-entry date.

What generic launch risks existed after the ruling?

After the invalidity judgment was affirmed, the patent-specific launch risk for Watson fell substantially.

Risk category	Post-decision assessment
U.S. Patent No. 8,673,921	Low, because the asserted claims were held invalid
Other Yaz patents	Potentially relevant if separately listed and enforceable
Regulatory approval	Dependent on FDA review of Watson's ANDA
Labeling and use restrictions	Dependent on the approved generic label
Manufacturing patents	No surviving barrier established by this case
Formulation patents	No surviving barrier established by this case
Antitrust or settlement exposure	No reported settlement issue in the appellate decision

The ruling did not automatically resolve every possible patent associated with Yaz. It resolved the patent claims actually asserted in this action. Other patents, exclusivities, regulatory requirements, or product-specific issues could have affected approval or launch timing.

How does this case compare with a composition-of-matter patent dispute?

Bayer v. Watson was materially different from litigation involving a valid compound patent.

Factor	Bayer v. Watson	Composition-of-matter case
Core patent	Regimen and method claims	Active pharmaceutical ingredient
Prior-art exposure	Relatively high	Usually lower if the compound is genuinely novel
Invalidation risk	Significant obviousness risk	Depends heavily on novelty and inventive step
Commercial protection	Narrower	Broader
Generic design-around options	More available	More limited
Effect of invalidity	Removes regimen-based barrier	Can permit unrestricted product entry

Regimen patents can extend product protection after primary compound patents expire, but their value depends on clinical unpredictability, claim breadth, supporting data, and the distance between the claimed regimen and the prior art.

What is the current legal significance of the case?

The decision is frequently cited for obviousness analysis in pharmaceutical patent litigation. It confirms that:

• A known combination of active ingredients may be obvious when the prior art provides a reason to combine them.
• A dosing regimen may be obvious when it is a predictable modification of known schedules.
• Commercial success does not overcome a strong prima facie obviousness case without a sufficient nexus to the claimed invention.
• Secondary considerations must be tied to the patented features rather than to the product's general commercial success.
• A Paragraph IV ANDA challenge can eliminate an Orange Book-listed patent before generic launch.

The case also demonstrates the commercial limits of secondary patenting strategies. A regimen patent can delay generic competition only if the claims survive validity challenges and cover commercially important product use.

Key Takeaways

• Bayer sued Watson in the District of Delaware over a Paragraph IV ANDA for generic Yaz.
• The asserted patent was U.S. Patent No. 8,673,921.
• The patent covered a drospirenone and ethinyl estradiol contraceptive regimen.
• The district court held the asserted claims obvious.
• The Federal Circuit affirmed in 2017.
• The ruling removed the patent-based obstacle to Watson's proposed generic product.
• The case did not involve a biologic, biosimilar, or manufacturing-process patent.
• The outcome weakened Bayer's secondary patent protection for Yaz.
• No settlement-based launch date or authorized-generic arrangement was established in the controlling appellate decision.

FAQs About Bayer Pharma AG v. Watson Laboratories

What product was involved in Bayer Pharma AG v. Watson?

The case involved Yaz, Bayer's combined oral contraceptive containing drospirenone and ethinyl estradiol.

What patent did Bayer assert against Watson?

Bayer asserted U.S. Patent No. 8,673,921, directed to a contraceptive regimen using drospirenone and ethinyl estradiol.

Did Watson win the Bayer patent case?

Yes. Watson prevailed on patent validity after the district court held the asserted claims obvious and the Federal Circuit affirmed.

Did Bayer obtain an injunction against the Yaz generic?

No continuing injunction could be based on the asserted patent after the courts held its claims invalid.

Is Bayer v. Watson relevant to biosimilar litigation?

No. The case involved a small-molecule oral contraceptive and an ANDA, not a biologic licensed under the biosimilar pathway.

References

1. Bayer Pharma AG v. Watson Laboratories, Inc., 874 F.3d 1316 (Fed. Cir. 2017).

2. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.